INOMAX Is Indicated for the Treatment of Hypoxic Respiratory Failure (HRF) in Term and Near-Term Infants |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX must not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
About INOMAX
INOMAX has been shown to provide:
|
|
|
|
In addition to INOMAX (nitic oxide) for inhalation, you get all the critical drug delivery systems required for INOMAX administration and that meet all FDA-required specifications, including:
 |
 |
 |
|
INOmax DSIR offers functional enhancements to INOmax DS. |
INOmax DS developed for bedside or transport situations. |
INOvent a bedside delivery system for INOMAX. |
Receive a broad range of support with INOtherapy—a comprehensive program that includes INOMAX (nitric oxide) for inhalation, all the critical equipment needed, expert support 24/7 and reimbursement support services.
To learn more or to schedule an appointment with one of your INOMAX representatives, medical science liaisons, or service technicians, please call 1-877-566-9466. For additional information, please Contact Us.
References
1. Golombek SG, Young JN. Efficacy of inhaled nitric oxide for hypoxic respiratory failure in term and late preterm infants by baseline severity of illness: a pooled analysis of three clinical trials. Clin Ther. 2010;32(5):939-948.
2. Data on file. Hampton, NJ: Ikaria®; 2012.